Clinical Trial Update: APalutamiAPalutamide and stEReotactic Body Radiation Therapy for Metastatic Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update exploring apalutamide with stereotactic body radiation therapy for oligometastatic hormone-sensitive prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone Sensitive Prostate Cancer
• Oligometastatic Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Apalutamide (apalutamide)
• Stereotactic Body Radiation Therapy (SBRT)

Snippet

Sponsor: Azienda Ospedaliero-Universitaria Careggi | Conditions: Oligometastatic Hormone Sensitive Prostate Cancer | Phase 2 | Status: UNKNOWN